middle.news
How Race Oncology’s RC220 Trial Milestones Are Narrowing Its FY2025 Loss
4:45pm on Tuesday 26th of August, 2025 AEST
•
Healthcare
Read Story
How Race Oncology’s RC220 Trial Milestones Are Narrowing Its FY2025 Loss
4:45pm on Tuesday 26th of August, 2025 AEST
Key Points
Loss narrowed to $4.79 million from $13.82 million in FY2024
Successful first dosing of RC220 and combination with doxorubicin in Phase 1 trial
Board renewal with new appointments including Executive Chair and independent directors
Termination of global IP license with City of Hope to consolidate intellectual property
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Racura Oncology (ASX:RAC)
OPEN ARTICLE